Clinical Trial Update: Study of Brolucizumab in Adult Patients With Suboptimal Anatomically Controlled Neovascular Age-related Macular Degeneration [Phase 3]

View source ↗

Summary

A Phase 3 study of brolucizumab in adults with suboptimally anatomically controlled neovascular age-related macular degeneration has completed and posted result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration

Drugs mentioned

• BEOVU (BROLUCIZUMAB)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Neovascular Age-Related Macular Degeneration | Phase 3 | Status: COMPLETED | Results posted: 2024-11-07